Equillium Reports Second Quarter 2019 Financial Results and Recent Highlights
12. August 2019 16:07 ET
|
Equillium
Initiated Phase 1b EQUIP proof-of-concept trial evaluating itolizumab (EQ001) for the treatment of uncontrolled asthma Investigational New Drug (IND) application accepted by FDA for itolizumab for...
Equillium Announces Initiation of the EQUIP Phase 1b Clinical Trial of Itolizumab for Patients with Uncontrolled Asthma
10. Juli 2019 08:07 ET
|
Equillium
LA JOLLA, Calif., July 10, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe...
Equillium to Present at Jefferies 2019 Healthcare Conference
23. Mai 2019 16:07 ET
|
Equillium
LA JOLLA, Calif., May 23, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium Reports First Quarter 2019 Financial Results and Recent Highlights
13. Mai 2019 16:07 ET
|
Equillium
EQUATE Phase 1b/2 trial in acute graft-versus-host disease (aGVHD) ongoing with data expected in 1Q 2020 On track to initiate Phase 1b proof-of-concept trials of itolizumab (EQ001) in uncontrolled...
Equillium Expands Scientific and Clinical Advisory Team
06. Mai 2019 08:30 ET
|
Equillium
LA JOLLA, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium to Present at Solebury Trout Class of 2018 Biotech IPO Investor Day
16. April 2019 16:07 ET
|
Equillium
LA JOLLA, Calif., April 16, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that Bruce...
Equillium to Present at H.C. Wainwright Global Life Sciences Conference
28. März 2019 16:07 ET
|
Equillium
LA JOLLA, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that Dan...
Equillium Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights
27. März 2019 16:07 ET
|
Equillium
LA JOLLA, Calif., March 27, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe...
Equillium Announces Plan to Develop EQ001 for the Treatment of Lupus Nephritis
26. Februar 2019 16:07 ET
|
Equillium
Clinical trial evaluating EQ001 for the treatment of refractory lupus nephritis to commence in 2H 2019 Ongoing EQ001 development programs in acute graft-versus-host disease and severe asthma remain...
Equillium to Present at Leerink Partners Global Healthcare Conference
21. Februar 2019 16:07 ET
|
Equillium
LA JOLLA, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immune-inflammatory disorders, announced today that Bruce...